[go: up one dir, main page]

MX2016011885A - Anticuerpo con actividad inhibidora de inyeccion frente al virus de hepatitis c. - Google Patents

Anticuerpo con actividad inhibidora de inyeccion frente al virus de hepatitis c.

Info

Publication number
MX2016011885A
MX2016011885A MX2016011885A MX2016011885A MX2016011885A MX 2016011885 A MX2016011885 A MX 2016011885A MX 2016011885 A MX2016011885 A MX 2016011885A MX 2016011885 A MX2016011885 A MX 2016011885A MX 2016011885 A MX2016011885 A MX 2016011885A
Authority
MX
Mexico
Prior art keywords
hepatitis
virus
injection
antibody
activity
Prior art date
Application number
MX2016011885A
Other languages
English (en)
Inventor
Wakita Takaji
Shinohara Midori
Yokokawa Hiroshi
Nakamura Noriko
Original Assignee
Japan As Represented By Director-General Of Nat Inst Of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By Director-General Of Nat Inst Of Infectious Diseases filed Critical Japan As Represented By Director-General Of Nat Inst Of Infectious Diseases
Publication of MX2016011885A publication Critical patent/MX2016011885A/es

Links

Classifications

    • C07K16/118—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La presente invención proporciona un anticuerpo de proteína E2 anti-virus de hepatitis C o uno de sus fragmentos de anticuerpo de unión al antígeno con actividad inhibidora de infección frente al virus de hepatitis C (HCV). La presente invención además proporciona un anticuerpo de proteína E2 antivirus de hepatitis c o uno de sus fragmentos de anticuerpo de unión al antígeno que comprende una cierta región variable, que tiene actividad inhibidora de la infección frente al virus de hepatitis C (HCV) y exhibe una propiedad supresora de la aparición del mutante de escape.
MX2016011885A 2014-03-20 2015-03-20 Anticuerpo con actividad inhibidora de inyeccion frente al virus de hepatitis c. MX2016011885A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014058936 2014-03-20
PCT/JP2015/058446 WO2015141826A1 (ja) 2014-03-20 2015-03-20 Ｃ型肝炎ウイルスに対する感染阻害活性を有する抗体

Publications (1)

Publication Number Publication Date
MX2016011885A true MX2016011885A (es) 2016-12-02

Family

ID=54144787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011885A MX2016011885A (es) 2014-03-20 2015-03-20 Anticuerpo con actividad inhibidora de inyeccion frente al virus de hepatitis c.

Country Status (9)

Country Link
US (1) US20170107273A1 (es)
EP (1) EP3121273A4 (es)
JP (1) JPWO2015141826A1 (es)
CN (1) CN106661568A (es)
BR (1) BR112016021576A2 (es)
CA (1) CA2942540A1 (es)
MX (1) MX2016011885A (es)
TW (1) TW201620931A (es)
WO (1) WO2015141826A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884169B (zh) 2016-01-22 2022-03-22 默沙东公司 抗凝血因子xi抗体
CN109476758B (zh) 2016-06-14 2023-05-23 默沙东有限责任公司 抗-凝血因子xi抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
JP2008532559A (ja) * 2005-03-19 2008-08-21 メディカル リサーチ カウンシル ウイルス感染の治療及び予防又は治療及び予防の改善
WO2007143701A2 (en) * 2006-06-06 2007-12-13 Progenics Pharmaceuticals, Inc. Monoclonal antibodies that potently neutralize hepatitis c virus (hcv) of diverse genotypes
WO2009014216A1 (ja) * 2007-07-25 2009-01-29 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
WO2010047830A2 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
CN102596996B (zh) * 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
US20130084301A1 (en) * 2011-08-30 2013-04-04 Steven Foung Cluster of Neutralizing Antibodies to Hepatitis C Virus

Also Published As

Publication number Publication date
TW201620931A (zh) 2016-06-16
BR112016021576A2 (pt) 2017-10-10
EP3121273A1 (en) 2017-01-25
JPWO2015141826A1 (ja) 2017-04-13
CA2942540A1 (en) 2015-09-24
CN106661568A (zh) 2017-05-10
WO2015141826A1 (ja) 2015-09-24
EP3121273A4 (en) 2017-08-30
US20170107273A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
IL284044A (en) Antibodies that neutralize hepatitis b virus and uses thereof
IL268891A (en) Polyploid adeno-associated virus vectors and methods of making and using the same
EP3794492C0 (en) Trusted contextual content
IL280559A (en) Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
CL2018000089A1 (es) Compuesto de elastómero reforzado con sílice y productos que lo contengan
EA201791773A1 (ru) Цистеиновая протеаза
EA201791775A1 (ru) Цистеиновая протеаза
SI4140297T1 (sl) Miši z gensko spremenjeno lahko verigo lambda imunoglobulina in njihova uporaba
EA201691993A1 (ru) Вакцина к вирусу эпидемической диареи свиней
EA202190822A1 (ru) Технологии для выполнения действий на основе обнаружения объектов
EP3538648A4 (en) RECOMBINANT VIRUS, COMPOSITION COMPRISING SAME AND CORRESPONDING USES
ECSP19018327A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
ZA201900154B (en) Temperature-sensitive attenuating strain of foot-and-mouth disease virus, construction method therefor and uses thereof
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
BR112016016035A2 (pt) gene resistente à praga antropogênica, anticorpo de cadeia única de idiotípico de toxina anti-cry1ab codificado pelo mesmo e aplicação
MX378905B (es) Pestivirus.
IL281698A (en) Monomer and multimeric anti-hbv agents
SG10201905229VA (en) Anti-Dengue Virus Antibodies and Applications Thereof
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
KR101882087B1 (ko) 어류 바이러스성 출혈성 패혈증 바이러스에 특이적인 단클론항체 및 이의 용도
EP3625349A4 (en) MODIFIED VIRUSES
EP3689906C0 (en) IL-5 ANTIBODIES, ITS ANTIGEN-BINDING FRAGMENT, AND ITS MEDICAL USES
PH12018502286A1 (en) Rt-pcr-hrm or pcr-hrm primer, reagent and method for rapidly distinguishing four serotypes of dengue virus
MX2016011885A (es) Anticuerpo con actividad inhibidora de inyeccion frente al virus de hepatitis c.
EP3401336A4 (en) ANTI-PCSK9 ANTIBODIES, ASSOCIATED ANTIGEN BINDING FRAGMENT, AND ASSOCIATED MEDICAL APPLICATION